Gilead Sciences, Inc. (GILD) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Gilead management told investors at the Citi Global Healthcare Conference that the company has seen a strong start to 2025, raised full-year guidance following robust third-quarter results, and is carrying significant commercial momentum. Growth is being driven by flagship HIV franchises Biktarvy and Descovy, while recent launches—Yeztugo (a six-month HIV prevention injection) and Livdelzi for primary biliary cholangitis—are described as off to strong starts; management also emphasized a deep pipeline that could provide ongoing data-driven catalysts.

Analysis

Market structure: Gilead (GILD) is the clear direct beneficiary — Yeztugo (6‑month injectable PrEP) and Livdelzi launches can shift share in prevention and rare liver disease markets and strengthen pricing power if payer coverage exceeds ~70–80% within 6–12 months. Losers: generic ARV suppliers (e.g., Viatris VTRS) and incumbents tied to oral-only prevention will see margin pressure and share loss; GSK (GSK) exposure to ViiV’s cabotegravir is the biggest near-peer competitive risk. Supply/demand: demand signals look strong but manufacturability for long‑acting injectables creates a ~3–9 month cadence risk that can cap upside if net product supply cannot scale.

Risk assessment: tail risks include an adverse label/reimbursement decision, manufacturing batch failures, or a surprise pipeline readout miss; each could remove 10–30% of upside in 3–12 months. Time horizons: expect price moves immediately (days) on conference/earnings, uptake-driven revenue changes in weeks–months, and pipeline-driven re-rating over quarters–years. Hidden dependencies: revenue concentration in Biktarvy/Descovy and successful shift to injectables; second‑order effects include payer-imposed step therapy that cannibalizes ASPs. Key catalysts: next 60–120 days of uptake metrics, FY25 guidance updates, and any payer coverage announcements.

Trade implications: actionable strategies are to establish a measured long in GILD (see decisions) and hedge competitive exposure (pair trades versus GSK) while using options to define downside. If IV compresses post-conference, favor buying 12–18 month LEAP calls 10–15% OTM or 6‑month call spreads ahead of quarterly sales prints; sell short‑dated calls only after a 20%+ run. Sector rotation: overweight large‑cap integrated biotech/innovators and underweight generic drugmakers (VTRS) for 3–12 months.

Contrarian angles: consensus likely underestimates payer pushback and supply constraints — upside may be front‑loaded then stall; conversely, consensus may underprice sustained HIV revenue if Yeztugo reduces incidence and increases lifetime treatment uptake, which would be a multi‑year booster. Historical parallel: Apretude saw rapid early adoption then payer restrictions; similar pattern could cap GILD’s short‑term multiple but preserve long‑term cash flow. Monitor 90‑day prescription growth, payer formulary inclusion rates, and manufacturing lot release timelines as early warning indicators.

Key Decisions for Investors

• Establish a 3% portfolio long position in GILD within the next 5 trading days, scale to 4–5% only if 90‑day launch metrics show >15k monthly Yeztugo administrations or payer coverage >70% reported within 90 days.
• Pair trade: go long GILD (3%) and short GSK (GSK) 1–2% to hedge competitive risk from ViiV; rebalance if GSK reports >10% upside on Cabotegravir uptake or if payers grant broad class coverage to injectables.
• Options: buy Jan 2027 LEAP calls on GILD ~10–15% OTM (size = 25–35% of cash position) to capture multi‑quarter pipeline upside, or execute a 6‑month call spread (debit) around the next quarterly sales print to limit premium paid.
• Reduce exposure to generic antiretroviral makers (e.g., Viatris VTRS) by 50% over 1–3 months as pricing/mix risk rises; redeploy proceeds into GILD and large‑cap innovators.
• Set objective exit/review thresholds: take partial profits on GILD at +20% nominal gain or if net product sales miss guidance by >5% over two consecutive quarters; cut positions if manufacturing/coverage shortfalls exceed the 3–9 month risk window.